Dextropropoxyphene
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
Opicapone
COMT Inhibitor · Parkinson's disease
Also known as Ongentys
COMT InhibitorParkinson's disease
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
8 major
SEVERE in our sources
PREGNANCY
Avoid—no information available.
FDA category + note
Top interactionssee all 8 →
- DextropropoxypheneSevereDatabaseDDInter
- IsocarboxazidSevereDatabaseDDInter
- LinezolidSevereDatabaseDDInter
- Methylene BlueSevereDatabaseDDInter
Mechanism
Opicapone is a long-acting, peripherally selective catechol-O-methyl transferase (COMT) inhibitor. It works by diminishing the peripheral metabolism of levodopa. This action prolongs the presence of levodopa in the system, thereby decreasing its clearance and increasing its relative bioavailability to the brain.
Indications
Adjunct to co-beneldopa or co-careldopa in Parkinson’s disease with ‘end-of-dose’ motor fluctuations (under expert supervision)Parkinson's disease (adjunct to L-DOPA)Adjunctive PD therapy for wearing off
Dosing
- Adult
- 50 mg once daily, dose to be taken at bedtime, at least one hour before or after levodopa combinations
- Hepatic adjustment
- Manufacturer advises avoid
- Geriatric
- elderly over 85 years (limited information available)
Pharmacokinetics
Duration
long-acting
Half-life
short plasma t1/2, but slow dissociation rate allows once daily use
Contraindications
- Catecholamine-secreting neoplasms
- history of neuroleptic malignant syndrome
- history of non-traumatic rhabdomyolysis
- paraganglioma
- phaeochromocytoma
Side effects
Common
Constipationdizzinessdrowsinessdry mouthhallucinationsheadachehypotensionmovement disordersmuscle complaintssleep disordersvomiting
Serious
- dyskinesias
- neuroleptic malignant syndrome
- rhabdomyolysis
Pregnancy & lactation
Pregnancy
Avoid—no information available.
Lactation
Avoid—present in milk in animal studies.
Drug interactions
Isocarboxazid
Severe
Database
Clinical effect not specified
Source: DDInter
Linezolid
Severe
Database
Clinical effect not specified
Source: DDInter
Methylene Blue
Severe
Database
Clinical effect not specified
Source: DDInter
Phenelzine
Severe
Database
Clinical effect not specified
Source: DDInter
Procarbazine
Severe
Database
Clinical effect not specified
Source: DDInter
Sodium Oxybate
Severe
Database
Clinical effect not specified
Source: DDInter
Tranylcypromine
Severe
Database
Clinical effect not specified
Source: DDInter
4 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Coeliac disease
OTHER · Gastroenterology · 2016
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Chronic kidney disease — assessment and management
NICE · Nephrology · 2021
Diabetes management in chronic kidney disease
KDIGO · Nephrology · 2022
Other COMT Inhibitor drugs
Ask House about Opicapone
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team